<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905421</url>
  </required_header>
  <id_info>
    <org_study_id>19-000630</org_study_id>
    <nct_id>NCT03905421</nct_id>
  </id_info>
  <brief_title>Quality of Life Assessed With the PAH SYMPACT Questionnaire</brief_title>
  <official_title>Quality of Life Assessed With the PAH SYMPACT Questionnaire in the Pulmonary Hypertension Clinic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are evaluating quality of life in pulmonary hypertension subjects using the
      Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire and assessing
      the questionnaires' performance with regard to relationship to other markers of disease
      severity, response to treatment, and outcome in a clinical practice setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be recruited from among those seen at the Mayo Pulmonary Hypertension Clinic.
      The PAH-SYMPACT questionnaire will be administered either in written form or by telephone
      interview.

      On the second 100 patients implement a standardized palliative care referral program for
      patients with Group 1 and 3 PH and high SYMPACT scores&gt; 1.0.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 6, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life in pulmonary hypertension subjects</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life in pulmonary hypertension subjects</measure>
    <time_frame>14 months</time_frame>
    <description>Measured using the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT) Questionnaire using a scale of 0=no, 1=mild, 2=moderate, 3=severe, and 4=very severe</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>usual care</arm_group_label>
    <description>The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. They will not be randomized to palliative care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>palliative care</arm_group_label>
    <description>The patient will be seen in the PH clinic and will be approached to consent and participate in the SYMPACT trial. Based on the patients in Group 1 and 3 PH and a high SYMPACT score&gt; 1.0 in any domain they will be randomized to receive standard care or a palliative care initial consult.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will be recruited from among those seen at the Mayo Pulmonary Hypertension Clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or above

          -  Consents to participate

          -  Documented group I PAH based upon these hemodynamic criteria: (mPAP &gt; 20, PCW 18 or
             less, PVR &gt; 3 Wood units

          -  Mean PAP &gt; 20, PCW â‰¤ 18, PVR &gt; 3 Wood units

          -  Parenchymal lung disease that in the opinion of the investigator qualifies patient as
             group III PH

          -  Documented chronic thromboembolic pulmonary hypertension or chronic thromboembolic
             disease with intent to treat with surgery, balloon pulmonary angioplasty, and/or PH
             medication

        Exclusion Criteria:

          -  Left sided heart disease (LVEF&lt;50%, PAWP&gt;18)

          -  Any other known concomitant life-threatening disease with a life expectancy &lt;12 months

          -  Any other clinically relevant and/or serious chronic medical condition that would
             affect study participation in the opinion of the investigator

          -  Non English speaking
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilary M DuBrock, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 13, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>July 24, 2019</last_update_submitted>
  <last_update_submitted_qc>July 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Hilary M. DuBrock,</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

